Immunic (NASDAQ:IMUX) Stock Rating Upgraded by Wall Street Zen

Immunic (NASDAQ:IMUX) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

IMUX has been the topic of several other reports. Roth Capital reiterated a “buy” rating and set a $19.00 price target on shares of Immunic in a research note on Thursday, May 14th. Wolfe Research started coverage on shares of Immunic in a research note on Friday, May 22nd. They issued an “outperform” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunic in a report on Friday, May 29th. LADENBURG THALM/SH SH raised Immunic to a “strong-buy” rating in a report on Wednesday, July 29th. Finally, Lifesci Capital upgraded Immunic to a “strong-buy” rating in a research report on Monday, May 4th. Three equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $47.57.

Immunic Price Performance

Shares of Immunic stock opened at $16.06 on Friday. Immunic has a 52 week low of $5.06 and a 52 week high of $16.86. The firm’s 50 day moving average is $14.45 and its two-hundred day moving average is $12.10. The firm has a market capitalization of $219.06 million, a P/E ratio of -3.67 and a beta of 1.41.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.36. As a group, research analysts expect that Immunic will post -3.93 earnings per share for the current fiscal year.

Institutional Trading of Immunic

Several institutional investors and hedge funds have recently bought and sold shares of IMUX. Jane Street Group LLC raised its position in Immunic by 279.3% in the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock valued at $226,000 after purchasing an additional 152,726 shares during the last quarter. Vanguard Group Inc. grew its position in Immunic by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock worth $3,832,000 after purchasing an additional 219,957 shares during the last quarter. Squarepoint Ops LLC purchased a new position in Immunic during the 3rd quarter worth $239,000. Two Sigma Investments LP acquired a new position in Immunic in the third quarter valued at $52,000. Finally, Virtu Financial LLC acquired a new position in Immunic in the third quarter valued at $99,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

More Immunic News

Here are the key news stories impacting Immunic this week:

• Positive Sentiment: HC Wainwright significantly improved its earnings forecasts across 2026–2030. The firm now projects smaller losses of $3.18 per share in 2026, $2.47 in 2027, $1.45 in 2028 and $0.53 in 2029, followed by positive EPS of $0.40 in 2030. HC Wainwright maintained a Buy rating and a $22 price target, suggesting potential upside from current levels.
• Positive Sentiment: HC Wainwright also raised its third- and fourth-quarter 2026 EPS estimates to losses of $0.74 and $0.68, respectively, from substantially larger projected losses. This indicates expectations for improved operating performance and a faster path toward profitability.
• Positive Sentiment: Brookline Capital Markets raised its full-year 2026 EPS forecast to a $3.86 loss from a $4.34 loss and improved its third-quarter estimate to a $0.84 loss from $1.07, reinforcing the view that Immunic’s near-term losses could narrow.
• Neutral Sentiment: Wall Street Zen upgraded its assessment of Immunic to Hold. The rating is less bullish than HC Wainwright’s view and could limit enthusiasm among investors seeking a stronger consensus signal. Immunic Raised to Hold at Wall Street Zen
• Negative Sentiment: Brookline slightly reduced its fourth-quarter 2026 estimate to a $1.16-per-share loss from $1.14. More broadly, Immunic remains unprofitable, with the analyst consensus calling for a $4.49-per-share loss in the current year. The company’s valuation therefore remains highly dependent on successful development and eventual commercialization of its pipeline.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.